Response Genetics, Inc. to Release First Quarter 2008 Financial Results and Present at the Rodman & Renshaw Fifth Annual Global Healthcare Conference

Response Genetics, Inc. (NASDAQ: RGDX) will announce first quarter 2008

financial results in a press release Thursday, May 15 after close of

market.
Response Genetics, Inc. also announced today that Kathleen Danenberg

President and CEO of Response Genetics, Inc., will present at the Rodman

& Renshaw Fifth Annual Global Healthcare Conference at 5:15 p.m. CET /

11:15 a.m. ET / 8:15 a.m. PT on Monday, May 19. The conference is being

held at Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.
The presentation will be made available by webcast and can be accessed

at www.responsegenetics.com.
About Response Genetics, Inc.
Response Genetics, Inc. ("RGI") (the "Company")

(NASDAQ: RGDX) is engaged in the research and development of

pharmacogenomic cancer diagnostic tests based on its proprietary and

patented technologies. RGI´s technologies enable extraction and analysis

of genetic information from genes derived from tumor samples stored as

formalin-fixed and paraffin embedded specimens. RGI currently generates

revenue primarily from the sales of its proprietary analytical

pharmacogenomic testing services of clinical trial specimens to the

pharmaceutical industry. The Company was founded in 1999 and its

principal headquarters are located in Los Angeles, California. For more

information, please visit www.responsegenetics.com.
Forward Looking Statement Notice
Except for the historical information contained herein, this press

release and the statements of representatives of RGI related thereto

contain or may contain, among other things, certain forward-looking

statements, within the meaning of the Private Securities Litigation

Reform Act of 1995.
Such forward-looking statements involve significant risks and

uncertainties. Such statements may include, without limitation

statements with respect to the Company´s plans, objectives, projections

expectations and intentions, such as the ability of the Company to

analyze cancer samples, the potential for using the results of this

research to develop diagnostic tests for cancer, the usefulness of

genetic information to tailor treatment to patients, the ability of the

Company to make its ResponseDx:LungTM and

ResponseDX:ColonTM tests available in a number

of institutions, and other statements identified by words such as

"projects," "may," "could," "would," "should," "believes," "expects,"

"anticipates," "estimates," "intends," "plans" or similar expressions.
These statements are based upon the current beliefs and expectations of

the Company´s management and are subject to significant risks and

uncertainties, including those detailed in the Company´s filings with

the Securities and Exchange Commission. Actual results, including

without limitation, actual sales results, if any, or the application of

funds, may differ from those set forth in the forward-looking

statements. These forward-looking statements involve certain risks and

uncertainties that are subject to change based on various factors (many

of which are beyond the Company´s control). The Company undertakes no

obligation to publicly update forward-looking statements, whether

because of new information, future events or otherwise, except as

required by law.